We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+2.69%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$8.16B
AUM Growth
+$296M
Cap. Flow
-$1.61B
Cap. Flow %
-19.71%
Top 10 Hldgs %
74.41%
Holding
114
New
7
Increased
22
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$80.1M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$65.5M
3
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$58.8M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$48.9M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$35.8M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$84.5M
2
CHTP
CHELSEA THERAPEUTICS INT'L LTD
CHTP
+$37.3M
3
HALO icon
Halozyme
HALO
+$24.8M
4
GILD icon
Gilead Sciences
GILD
+$23.4M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 44.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FMI
76
DELISTED
Foundation Medicine, Inc.
FMI
$2.11M 0.03%
+78,162
New +$1.98M
MDGL icon
77
Madrigal Pharmaceuticals
MDGL
$11.9B
$2.04M 0.03%
14,286
– –
LJPC
78
DELISTED
La Jolla Pharmaceutical Company
LJPC
$2.04M 0.02%
221,631
– –
OSUR icon
79
OraSure Technologies
OSUR
$268M
$2.02M 0.02%
234,664
– –
RIGL icon
80
Rigel Pharmaceuticals
RIGL
$857M
$1.75M 0.02%
48,197
– –
FOLD
81
DELISTED
Amicus Therapeutics
FOLD
$1.61M 0.02%
481,697
– –
ISEE
82
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.56M 0.02%
36,776
– –
AKAO
83
DELISTED
Achaogen Inc
AKAO
$1.4M 0.02%
100,000
– –
GERN icon
84
Geron
GERN
$977M
$1.29M 0.02%
425,981
– –
RCPT
85
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$1.02M 0.01%
23,900
– –
TCRT icon
86
Alaunos Therapeutics
TCRT
$4.47M
$986K 0.01%
1,631
– –
XLRN
87
DELISTED
Acceleron Pharma
XLRN
$977K 0.01%
28,765
– –
TSRO
88
DELISTED
TESARO, Inc.
TSRO
$971K 0.01%
31,218
– –
ALNY icon
89
Alnylam Pharmaceuticals
ALNY
$31.6B
$733K 0.01%
11,600
– –
QURE icon
90
uniQure
QURE
$3.36B
$417K 0.01%
30,672
– –
FPRX
91
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$308K ﹤0.01%
19,823
– –
CCXI
92
DELISTED
ChemoCentryx, Inc.
CCXI
$293K ﹤0.01%
50,000
– –
ASMB icon
93
Assembly Biosciences
ASMB
$700M
– –
-6,962
Closed -$535K
PRTA icon
94
Prothena Corp
PRTA
$485M
– –
-230,142
Closed -$8.82M
SVRA icon
95
Savara
SVRA
$1.15B
– –
-42,857
Closed -$2.04M
TVTX icon
96
Travere Therapeutics
TVTX
$6.19B
– –
-197,178
Closed -$4.19M
ICPT
97
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-256,375
Closed -$84.5M
PTLA
98
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-182,591
Closed -$4.73M
AUXL
99
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
– –
-58,544
Closed -$1.59M
FURX
100
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
– –
-40,309
Closed -$3.51M
1 2 3
4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2014 Portfolio in Review

As of Q2 2014, Julian Baker held 114 positions worth $8.16B, up 3.8% from $7.87B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Julian Baker withdrew a net $1.61B in Q2 2014, closing 9 positions and reducing 9 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $84.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 48% a quarter earlier.

Against the trend, Julian Baker opened a new position in Aravive, Inc. Common Stock worth $34.9M.

  • Julian Baker's largest Q2 2014 buy was Aravive, Inc. Common Stock: 207,648 shares worth $34.9M.
  • Julian Baker added most to PHARMACYCLICS INC in Q2 2014, an estimated $80.1M increase.
  • Julian Baker's biggest Q2 2014 reduction was Halozyme, cutting an estimated $24.8M.
  • Julian Baker fully exited Intercept Pharmaceuticals, Inc. in Q2 2014, selling an estimated $84.5M.
  • Julian Baker's ten largest holdings make up 74% of its $8.16B portfolio in Q2 2014.
  • Julian Baker opened 7 new positions and closed 9 in Q2 2014.
  • Julian Baker's portfolio value rose 3.8% quarter-over-quarter to $8.16B.

Based on Baker Bros. Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.